CA2441048C - Novel compound for treatment of allergy and asthma - Google Patents

Novel compound for treatment of allergy and asthma Download PDF

Info

Publication number
CA2441048C
CA2441048C CA2441048A CA2441048A CA2441048C CA 2441048 C CA2441048 C CA 2441048C CA 2441048 A CA2441048 A CA 2441048A CA 2441048 A CA2441048 A CA 2441048A CA 2441048 C CA2441048 C CA 2441048C
Authority
CA
Canada
Prior art keywords
ige
fab
human
atopic
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2441048A
Other languages
English (en)
French (fr)
Other versions
CA2441048A1 (en
Inventor
Sylvia Laffer
Kenneth H. Roux
Wolfgang R. Sperr
Peter Valent
Dietrich Kraft
Rudolf Valenta
Erik Hoegbom
Jonas Adriansson
Hans Groenlund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phadia AB
Original Assignee
Phadia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phadia AB filed Critical Phadia AB
Publication of CA2441048A1 publication Critical patent/CA2441048A1/en
Application granted granted Critical
Publication of CA2441048C publication Critical patent/CA2441048C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2441048A 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma Expired - Lifetime CA2441048C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101093A SE0101093D0 (sv) 2001-03-28 2001-03-28 Novel compound for treatment of allergy and asthma
SE0101093-3 2001-03-28
PCT/SE2002/000636 WO2002079257A1 (en) 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma

Publications (2)

Publication Number Publication Date
CA2441048A1 CA2441048A1 (en) 2002-10-10
CA2441048C true CA2441048C (en) 2011-12-13

Family

ID=20283563

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2441048A Expired - Lifetime CA2441048C (en) 2001-03-28 2002-03-28 Novel compound for treatment of allergy and asthma

Country Status (7)

Country Link
US (2) US6986889B2 (enExample)
EP (1) EP1373322A1 (enExample)
JP (2) JP2005500992A (enExample)
AU (1) AU2002251624B8 (enExample)
CA (1) CA2441048C (enExample)
SE (1) SE0101093D0 (enExample)
WO (1) WO2002079257A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884877B2 (en) 2001-10-03 2005-04-26 Florida State University Research Foundation, Inc. Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
CA2624081C (en) * 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
JP2025533898A (ja) * 2022-10-07 2025-10-09 アブウィズ バイオ，インコーポレイテッド 抗ｉｇｅ抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
WO2000072879A1 (en) 1999-05-26 2000-12-07 Tanox, Inc. TREATING ALLERGIC DISEASES WITH IMMUNOTHERAPY AND IgE ANTAGONISTS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof
US10196458B2 (en) 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof

Also Published As

Publication number Publication date
JP2014012683A (ja) 2014-01-23
CA2441048A1 (en) 2002-10-10
SE0101093D0 (sv) 2001-03-28
US6986889B2 (en) 2006-01-17
AU2002251624A2 (en) 2008-05-01
US20030035796A1 (en) 2003-02-20
AU2002251624B8 (en) 2008-10-02
EP1373322A1 (en) 2004-01-02
WO2002079257A1 (en) 2002-10-10
USRE42324E1 (en) 2011-05-03
AU2002251624B2 (en) 2008-09-04
JP2005500992A (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
JP7258366B6 (ja) トランスサイレチン（ｔｔｒ）アミロイドーシスに対する抗体療法及びそのためのヒト由来抗体
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
JP3925663B2 (ja) 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
EP0885244B2 (en) Peptide immunogens for vaccination against and treatment of allergy
JP3920215B2 (ja) ヒトｍｃｐ−１に対する抗体
Kato et al. Structural basis of the interaction between IgG and Fcγ receptors
Flicker et al. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity
JPH08500487A (ja) Ｌ鎖欠落免疫グロブリン
US7888479B2 (en) Humanized antibodies against monocyte chemotactric proteins
Terness et al. The natural human IgG anti-F (ab') 2 antibody recognizes a conformational IgG1 hinge epitope.
USRE42324E1 (en) Compound for treatment of allergy and asthma
EP1169353B1 (en) Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor
EP0576439B1 (en) Monoclonal antibody against lps core
Laffer et al. A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcϵRI interaction and reacts with receptor-bound IgE
AU2002251624A1 (en) Novel compound for treatment of allergy and asthma
Levy et al. Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA.
Lupinek et al. Trimolecular complex formation of IgE, FcεRI, and a recombinant nonanaphylactic single-chain antibody fragment with high affinity for IgE
WO2010136196A1 (en) Immunoglobulin preparation for the treatment of autoimmune diseases and immune system disorders
HK1014962B (en) Peptide immunogens for vaccination against and treatment of allergy

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220328